Veracyte (VCYT) – Investment Analysts’ Weekly Ratings Changes

Veracyte (NASDAQ: VCYT) recently received a number of ratings updates from brokerages and research firms:

• 6/2/2026 – Veracyte is now covered by Wolfe Research. They set an “outperform” rating and a $55.00 price target on the stock.
• 6/1/2026 – Veracyte had its price target raised by Needham & Company LLC from $48.00 to $57.00. They now have a “buy” rating on the stock.
• 6/1/2026 – Veracyte was upgraded by Wolfe Research to “strong-buy”.
• 5/28/2026 – Veracyte had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $48.00 price target on the stock.
• 5/6/2026 – Veracyte had its price target raised by UBS Group AG from $48.00 to $52.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Veracyte had its price target raised by Canaccord Genuity Group Inc. from $40.00 to $42.00. They now have a “hold” rating on the stock.
• 4/20/2026 – Veracyte had its price target lowered by Canaccord Genuity Group Inc. from $43.00 to $40.00. They now have a “hold” rating on the stock.

Insider Buying and Selling

In other news, insider John Leite sold 13,975 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $50.07, for a total transaction of $699,728.25. Following the completion of the sale, the insider directly owned 132,305 shares of the company’s stock, valued at $6,624,511.35. This trade represents a 9.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Marc Stapley sold 138,051 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $50.12, for a total value of $6,919,116.12. Following the sale, the chief executive officer directly owned 440,494 shares of the company’s stock, valued at approximately $22,077,559.28. This represents a 23.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 202,967 shares of company stock worth $9,881,831 over the last quarter. Corporate insiders own 1.40% of the company’s stock.

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.